Make Informed Investment Decisions with Affordable Access to Experts

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Evaluating Potential Growth Prospects for Keryx's (KERX) Auryxia After Positive Phase III Data Evaluating Iron Deficiency Anemia Patients (IDA) With Stage 3-5 Non-Dialysis-Dependent Chronic Kidney Disease (NDD CKD)

Ticker(s): KERX

Who's the expert?

Name: Dr Edward Skolnik - MD

Institution: NYU

Bio:

  • Director of Division of Nephrology, Norman S. Wikler Professor of Medicine & Professor of Pharmacology at NYU Langone.
  • In practice for 33 years, double board certified in Nephrology and Internal Medicine, and has extensive experience treating patients with CKD and FSGS.
  • Published a number of articles in peer reviewed journals and member of several professional organizations including The American Society for Clinical Investigation

Interview Questions
Q1.

Can you describe your experience treating iron deficiency anemia in adults with non-dialysis dependent chronic kidney disease.? With no FDA approved treatments, what do you currently do to help your patients? 

Added By: pjloria
Q2.

 How do patients respond to current treatment options, including over the counter iron supplements and intravenous iron (Feraheme or Venofer)? How do these treatments compare to Auryxia?

Added By: pjloria
Q3.

What are the relative benefits of these treatment options? Are some treatment options better fit for certain patient subsets? 

Added By: pjloria
Q4.

Given the current data, what are the chances Auryxia is approved for the expanded indication? 

Added By: pjloria
Q5.

Data from the ESRD Phase III study showed a 24% reduction in repeat hospitalizations versus then standard of care (presumably due to reduced IV iron use).  So why has take-up been so slow?  How much is due to formulary access?

Added By: mudsharkox
Q6.

What are the differences in costs between current treatment options and Auryxia?

Added By: pjloria
Q7.

Assuming it gets approved, what percentage of existing patients do you expect to start taking Auryxia? What percentage do you expect to stay on IV iron or supplements? What percentage of new patients do you expect will choose each treatment option? 

Added By: pjloria
Q8.

Assuming it gets approved, how will an expanded indication change the perception of the iron black box warning for physicians? 

Added By: pjloria

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.